Literature DB >> 7758341

Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy.

K M Bannister1, A Weaver, A R Clarkson, A J Woodroffe.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7758341     DOI: 10.1159/000423895

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


× No keyword cloud information.
  8 in total

Review 1.  Blood pressure level and kidney disease progression: do we really need to go to 130/80 mm Hg?

Authors:  Bassam G Abu Jawdeh; Mahboob Rahman
Journal:  Curr Hypertens Rep       Date:  2009-10       Impact factor: 5.369

2.  Managing progressive renal disease before dialysis.

Authors:  B J Barrett
Journal:  Can Fam Physician       Date:  1999-04       Impact factor: 3.275

Review 3.  Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset.

Authors:  Nicholas Stoycheff; Kruti Pandya; Aghogho Okparavero; Abigail Schiff; Andrew S Levey; Tom Greene; Lesley A Stevens
Journal:  Nephrol Dial Transplant       Date:  2010-09-03       Impact factor: 5.992

Review 4.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 5.  Managing kidney disease with blood-pressure control.

Authors:  Elke Wühl; Franz Schaefer
Journal:  Nat Rev Nephrol       Date:  2011-06-21       Impact factor: 28.314

6.  Clinical course of patients with IgA nephropathy between combined treatment of immunosuppressive agents and ACE inhibitor and ACE inhibitor alone.

Authors:  Y C Hwang; T W Lee; M J Kim; M H Yang; C G Ihm
Journal:  Korean J Intern Med       Date:  2001-06       Impact factor: 2.884

Review 7.  Therapeutic strategies to slow chronic kidney disease progression.

Authors:  Elke Wühl; Franz Schaefer
Journal:  Pediatr Nephrol       Date:  2008-03-12       Impact factor: 3.714

8.  A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616].

Authors:  Ronald J Hogg; Robert J Wyatt
Journal:  BMC Nephrol       Date:  2004-03-25       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.